ZZV-12017-12523
1 vaccination
0 coded responses
6 check-ins
0 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 843 / UT
- Registered
- 2021-04-13
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-13
Registered in v-safe
-
2021-04-13
Dose 1 — Pfizer-BioNTech
-
2021-04-13
Health check-in — 0 day, dose 1Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tiredness, Nausea, Vomiting, Abdominal pain · Be unable to do your normal daily activitiesAdult check-in
-
2021-04-13
Report sent to call center — 0 day, dose 1Be unable to do your normal daily activities1 call case(s)
-
2021-04-14
Health check-in — days 1–6 daily, dose 1Feeling: Poor · Site: Pain · Fever · Headache, Muscle or body aches, Fatigue or tiredness, Nausea, Vomiting, Diarrhea, Abdominal pain · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
-
2021-04-14
Report sent to call center — days 1–6 daily, dose 1Be unable to work · Be unable to do your normal daily activities1 call case(s)
-
2021-04-15
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tiredness, Nausea, VomitingAdult check-in
-
2021-04-16
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tiredness, Nausea, VomitingAdult check-in
-
2021-04-17
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Fatigue or tiredness, NauseaAdult check-in
- 2021-04-22
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-13 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-04-13 | priority 2/3 | |
| 2021-04-14 | priority 2/3 |
Free text
None.
Free-text releases are not linked to a specific survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
No MedDRA codes.